Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer

ABSTRACT

PRECONNECT is a multicenter study demonstrating the efficacy and tolerability of trifluridine/tipiracil in adult patients with histologically confirmed adenocarcinoma of the colon or rectum and pretreated metastatic lesions. The current article describes the characteristics and outcomes of the Brazilian cohort of patients who underwent trifluridine/tipiracil therapy within PRECONNECT. Brazilian patients (n=55) received oral trifluridine/tipiracil 35mg/m² twice daily on days 1-5 and 8-12 of each 28-day cycle. The primary endpoint was safety including time to ECOG (Eastern Cooperative Oncology Group) PS (performance status) deterioration, and the secondary endpoints included progression-free survival (PFS) and quality of life (QoL). Baseline characteristics showed only 34.5% of patients underwent ≥3 lines of treatment, 29.1% presented ≥3 metastatic sites and 52.7% showed an ECOG PS of 0. The disease control rate (DCR) was 32.0% and 28.6% in patients with one and two metastatic sites, respectively, the median PFS was 3.0 months (95%CI: 2.5-3.4), and the time to ECOG PS deterioration (≥2) was 5.4 months. Drug-related treatment-emergent adverse events (TEAE) were observed at least once in 87.3% of patients, and the most common (≥40% of patients) hematological TEAEs were neutropenia and anemia; there was no febrile neutropenia case. The shorter time to ECOG PS deterioration showed in the Brazilian subset of patients is likely due to late diagnosis setting compared to the global population, despite that trifluridine/tipiracil showed good DCR results, including patients with two metastatic sites. In conclusion, safety and efficacy results provide confidence in routine practice use and are in line with the PRECONNECT study

RESUMO

O PRECONNECT é um estudo multicêntrico que demonstra a eficácia e tolerabilidade de trifluridina/tipiracil em pacientes adultos com adenocarcinoma de cólon ou reto confirmado histologicamente e lesões metastáticas pré-tratadas. O presente artigo descreve as características e os resultados da coorte brasileira de pacientes submetidos à terapia com trifluridina/tipiracil dentro do PRECONNECT. Pacientes brasileiros (n=55) receberam trifluridina/tipiracil oral 35mg/m² duas vezes ao dia, nos dias 1 -5 e 8-12 de cada ciclo de 28 dias. O desfecho primário foi a segurança, incluindo o tempo até a deterioração do ECOG (Eastern Cooperative Oncology Group) SD (status de desempenho), e os desfechos secundários incluíram sobrevida livre de progressão (SLP) e qualidade de vida (QV). As características basais mostraram que apenas 34,5% dos pacientes foram submetidos a ≥3 linhas de tratamento, 29,1% apresentaram ≥3 sítios metastáticos e 52,7% apresentaram ECOG SD de 0. A taxa de controle da doença (TCD) foi de 32,0% e 28,6% em pacientes com um e dois sítios metastáticos, respectivamente, a PFS mediana foi de 3,0 meses (IC95%: 2,5-3,4) e o tempo para deterioração do ECOG SD (≥2) foi de 5,4 meses. Os eventos adversos emergentes do tratamento (EAET) relacionados ao medicamento foram observados pelo menos uma vez em 87,3% dos pacientes, e os EAETs hematológicos mais comuns (≥40% dos pacientes) foram neutropenia e anemia; não houve caso de neutropenia febril. O menor tempo para deterioração do ECOG SD mostrado no subgrupo brasileiro de pacientes é provavelmente devido ao diagnóstico tardio em comparação com a população global, apesar de que trifluridina/tipiracil mostrou bons resultados de TCD, incluindo pacientes com dois sítios metastáticos. Em conclusão, os resultados de segurança e eficácia fornecem confiança no uso da prática de rotina e estão de acordo com o estudo PRECONNECT.

Keywords:

Trifluridine/tipiracil - Colorectal cancer - Metastatic colorectal cancer - Refractory disease

Descritores:

Trifluridina/tipiracil - Câncer colorretal - Câncer colorretal metastático - Doença refratária

FUNDING

This work was supported by Servier Pharmaceuticals.

DISCLOSURE

CALM reports research grants/funding received from Laboratórios Servier do Brasil and Servier.

Publikationsverlauf

Eingereicht: 29. Juli 2022

Angenommen: 23. September 2022

Artikel online veröffentlicht:
01. Dezember 2022

• REFERENCES

• 1 Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021; Oct; 14 (10) 101174-101174
• 2 Kohlschutter A, Schulz A. CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev 2016; Jun; 13 (Suppl 1): 682-688
• 3 Souza DL, Jerez-Roig J, Cabral FJ, Lima JR, Rutalira MK, Costa JA. Colorectal cancer mortality in Brazil: predictions until the year 2025 and cancer control implications. Dis Colon Rectum 2014; 57 (09) 1082-1089
• 4 Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J. et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 (Suppl 3): iii1-8
• 5 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020; 5 (01) 22-22
• 6 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; Aug; 27 (08) 1386-1422
• 7 Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014; Feb; 106 (02) djt371-djt371
• 8 Calcagno F, Lenoble S, Lakkis Z, Nguyen T, Limat S, Borg C. et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in french clinical practice. Clin Med Insights Oncol 2016; Jul; 10: 59-66
• 9 Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y. et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA 2018; 319 (24) 2486-2496
• 10 Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2018; Oct; 82 (06) 961-969
• 11 Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Gravalos C, Benavides M. et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 2018; Feb; 90: 63-72
• 12 Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; Apr; 55 (04) 475-482
• 13 Fietz M, AlSayed M, Burke D, Cohen-Pfeffer J, Cooper JD, Dvorakova L. et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab 2016; 119 (1-2): 160-167
• 14 Bachet JB, Wyrwicz L, Price T, Cremolini C, Phelip JM, Portales F. et al. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open 2020; 5 (03) e000698
• 15 Alsubaie L, Aloraini T, Amoudi M, Swaid A, Eyiad W, AI Mutairi F. et al. Genomic testing and counseling: The contribution of next-generation sequencing to epilepsy genetics. Ann Hum Genet 2020; Jun; 84 (06) 431-436
• 16 Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012; Oct; 13 (10) 993-1001
• 17 Ogata M, Kotaka M, Ogata T, Hatachi Y, Yasui H, Kato T. et al. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study in Japan. PLoS One 2020; Jun; 15 (06) e0234314
• 18 Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S. et al. Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian Compassionate Use Program. Oncologist 2018; 23 (10) 1178-1187
• 19 Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T. et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 2018; 23 (01) 7-15
• 20 Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol 2020; 31 (01) 88-95
• 21 Ireland PJ, McGill J, Zankl A, Ware RS, Pacey V, Ault J. et al. Functional performance in young Australian children with achondroplasia. Dev Med Child Neurol 2011; Aug; 53 (10) 944-950
• 22 Truty R, Patil N, Sankar R, Sullivan J, Millichap J, Carvill G. et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open 2019; Jun; 4 (03) 397-408
• 23 Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ. et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33 (28) 3199-3212